NASDAQ:MCRB

Seres Therapeutics Competitors

$21.39
+0.74 (+3.58 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.77
Now: $21.39
$22.13
50-Day Range
$17.66
MA: $20.12
$22.70
52-Week Range
$3.41
Now: $21.39
$38.50
Volume617,924 shs
Average Volume1.04 million shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.07

Competitors

Seres Therapeutics (NASDAQ:MCRB) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying MCRB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Seres Therapeutics, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Seres Therapeutics (NASDAQ:MCRB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Risk and Volatility

Seres Therapeutics has a beta of 4.07, suggesting that its stock price is 307% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Valuation and Earnings

This table compares Seres Therapeutics and Ultragenyx Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

Seres Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Seres Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seres Therapeutics01602.86
Ultragenyx Pharmaceutical06802.57

Seres Therapeutics currently has a consensus price target of $38.1667, suggesting a potential upside of 78.43%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, suggesting a potential upside of 20.73%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Seres Therapeutics and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seres Therapeutics-385.22%-2,867.98%-51.24%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Institutional & Insider Ownership

94.3% of Seres Therapeutics shares are held by institutional investors. 4.8% of Seres Therapeutics shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
Seres Therapeutics01602.86

Arrowhead Pharmaceuticals currently has a consensus price target of $85.3077, indicating a potential upside of 26.27%. Seres Therapeutics has a consensus price target of $38.1667, indicating a potential upside of 78.43%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its share price is 307% more volatile than the S&P 500.

Profitability

This table compares Arrowhead Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Earnings and Valuation

This table compares Arrowhead Pharmaceuticals and Seres Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.69$-84,550,000.00($0.84)-80.43
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83

Seres Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are owned by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics (NASDAQ:MCRB) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Seres Therapeutics and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08

GW Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Seres Therapeutics and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seres Therapeutics01602.86
GW Pharmaceuticals010402.29

Seres Therapeutics presently has a consensus target price of $38.1667, indicating a potential upside of 78.43%. GW Pharmaceuticals has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Seres Therapeutics is more favorable than GW Pharmaceuticals.

Volatility and Risk

Seres Therapeutics has a beta of 4.07, suggesting that its share price is 307% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares Seres Therapeutics and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seres Therapeutics-385.22%-2,867.98%-51.24%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Seres Therapeutics beats GW Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Valuation and Earnings

This table compares Ascendis Pharma A/S and Seres Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million441.02$-244,180,000.00($5.25)-23.41
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83

Seres Therapeutics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Ascendis Pharma A/S and Seres Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Seres Therapeutics01602.86

Ascendis Pharma A/S presently has a consensus price target of $187.6667, indicating a potential upside of 52.69%. Seres Therapeutics has a consensus price target of $38.1667, indicating a potential upside of 78.43%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Ascendis Pharma A/S.

Institutional & Insider Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Seres Therapeutics (NASDAQ:MCRB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Seres Therapeutics and TG Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seres Therapeutics01602.86
TG Therapeutics00503.00

Seres Therapeutics currently has a consensus price target of $38.1667, indicating a potential upside of 78.43%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 39.37%. Given Seres Therapeutics' higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than TG Therapeutics.

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Seres Therapeutics has a beta of 4.07, indicating that its stock price is 307% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Profitability

This table compares Seres Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seres Therapeutics-385.22%-2,867.98%-51.24%
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation and Earnings

This table compares Seres Therapeutics and TG Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83
TG Therapeutics$150,000.0043,038.06$-172,870,000.00($1.83)-25.09

Seres Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Seres Therapeutics beats TG Therapeutics on 10 of the 14 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and Seres Therapeutics (NASDAQ:MCRB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ionis Pharmaceuticals and Seres Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ionis Pharmaceuticals27602.27
Seres Therapeutics01602.86

Ionis Pharmaceuticals currently has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. Seres Therapeutics has a consensus target price of $38.1667, suggesting a potential upside of 78.43%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Ionis Pharmaceuticals.

Volatility & Risk

Ionis Pharmaceuticals has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500.

Earnings & Valuation

This table compares Ionis Pharmaceuticals and Seres Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$1.12 billion5.15$303.26 million$2.0819.73
Seres Therapeutics$34.51 million56.74$-70,280,000.00($1.20)-17.83

Ionis Pharmaceuticals has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ionis Pharmaceuticals7.82%6.57%3.39%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Institutional & Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Seres Therapeutics on 7 of the 13 factors compared between the two stocks.


Seres Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.56+0.6%$7.06 billion$87.99 million-80.43
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$122.91+1.0%$6.67 billion$14.98 million-14.97Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92+0.2%$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03+1.9%$5.78 billion$1.12 billion85.48
Allakos logo
ALLK
Allakos
1.7$105.33+2.7%$5.74 billionN/A-38.44Insider Selling
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48+0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18+0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95+0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56+1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06+1.1%$4.28 billion$204.89 million-36.33
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08+1.4%$4.10 billion$806.43 million-9.50Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28+1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83+2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74+4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11+1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37+0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23+3.6%$3.17 billionN/A-56.33Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69+2.6%$3.16 billion$42.98 million-25.27
Alkermes logo
ALKS
Alkermes
1.2$19.65+0.6%$3.15 billion$1.17 billion-42.72
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88+5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27+1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22+6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43+1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18+4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50+2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28+3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23+0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89+4.0%$2.41 billion$33.94 million-87.74Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.96+0.2%$2.25 billion$963.01 million13.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33+2.7%$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.